Fc-independent functions of anti-CTLA-4 antibodies contribute to anti-tumor efficacy

Ipilimumab, a monoclonal antibody that recognizes cytotoxic T-lymphocyte associated protein 4 (CTLA-4), was the first immune checkpoint inhibitor approved by the FDA to treat metastatic melanoma patients. Multiple preclinical studies have proposed that Fc effector functions of anti-CTLA-4 therapy ar...

Descripción completa

Detalles Bibliográficos
Autores principales: Sato, Yosuke, Casson, Cierra N., Matsuda, Atsushi, Kim, James I., Shi, Judy Qiuju, Iwasaki, Shinji, Chen, Susan, Modrell, Brett, Chan, Chingkit, Tavares, Daniel, Austen, Douglas, Ida, Koh, Tayber, Olga, Hein, Pyae, Comeau, Robert, Lin, Yafang, Shaw, Michael H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463231/
https://www.ncbi.nlm.nih.gov/pubmed/35237846
http://dx.doi.org/10.1007/s00262-022-03170-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463231/
https://www.ncbi.nlm.nih.gov/pubmed/35237846
http://dx.doi.org/10.1007/s00262-022-03170-z

Ejemplares similares